Detailed Narrative
Q3 FY25 Financial Performance Highlights
Aurobindo Pharma reported its highest ever quarterly revenues of ₹7,979 crores in Q3 FY25, demonstrating strong year-on-year and quarter-on-quarter growth. The gross contribution reached ₹4,663 crores, with gross margins maintained at 58.4%, an increase of 130 basis points year-on-year. EBITDA for the quarter stood at ₹1,628 crores, translating to a healthy margin of 20.4%, even after absorbing approximately ₹50 crores higher R&D costs compared to Q3 FY24. The net profit for the quarter was ₹846 crores.
Geographical Business Performance
The formulations business grew 11% year-on-year to ₹6,973 crores, contributing 87% of total revenues. The U.S. formulations business recorded revenues of US$435 million, up from US$421 million in Q2 FY25, with generic products revenue increasing 4% year-on-year to US$297 million. Europe formulations delivered strong results with a 23% year-on-year growth to ₹2,121 crores (€236 million). Growth markets saw a remarkable 39% year-on-year increase, reaching ₹873 crores or US$104 million, driven by geographical expansion and strong sales momentum. The ARV business contributed US$36 million (₹307 crores).
Strategic Initiatives and Capacity Expansion
Aurobindo is expanding its manufacturing capacities, with a present annual formulations capacity of 50 billion+ units. The China plant, with an annual OSD capacity of 2 billion units, was commercialized in November 2024 and is expected to contribute to revenues in FY26, primarily billing to European markets from April. The US-based OSD plant at Dayton and the Raleigh plant (for transdermal and respiratory products) are expected to be fully operational in the next fiscal year. The company is also building a strong respiratory and nasal portfolio, including a recent partnership with a global pharma major for respiratory product development.
Biosimilars Pipeline and Launch Timelines
The company received positive CHMP opinions for Filgrastim and long-acting Filgrastim, with marketing approvals expected in two months. Commercial supplies into the EU are anticipated to begin in July (Q1 FY26). The Denosumab clinical study is on track to conclude by May 2025, with the clinical study report expected by September 2025, leading to European filing in Q2 FY26 and US filing in Q4 FY26. The Omalizumab clinical study, despite some delays, is expected to conclude by the end of 2025, with a Q4 FY26 filing possibility in Europe. The Bevacizumab recruitment phase is expected to conclude in the next two quarters, with filing in Q1-Q2 FY26. The biosimilars business is projected to reach an inflection point between 2028 and 2030, with at least 7 products commercialized by 2027-28.
Pen-G and Eugia Operational Updates
The Pen-G plant incurred an operational loss of approximately ₹60 crores during the quarter due to a shutdown for equipment modification, but is expected to break even by March 2025, with ramp-up starting in April. Eugia Pharma Specialties Limited faced production problems, leading to capacity utilization of around 50%, impacting sales. However, all remedial actions have been completed, and the company expects to return to 60-70% capacity utilization from Q4 FY25 onwards, anticipating much better sales in Q4 FY25 and Q1 FY26. The Vizag plant for injectables is in nascent stages, with significant capacity expected to be available up to FY30.
Capital Allocation and Financial Health
Net Capex for the quarter was around US$106 million. The company's cash flows improved significantly, resulting in a net cash inflow of US$49 million and a reduction in net debt to US$84 million by December 2024, down from US$133 million in September 2024. The average finance cost for the quarter was 5.6%. Aurobindo Pharma is on track to achieve its internal EBITDA margin target of 21-22% for FY25, with Q4 FY25 expected to be strong due to increased transient📎 sales and strategic initiatives.